Antitope Ltd., UK (Antitope),a privately-held Cambridge UK-based biotechnology company, announced the completion of a research collaboration with Rottapharma Biotech Srl, the antibody research unit of the Italian healthcare company Rottapharm|Madaus, whereby Antitope applied is proprietary EpiScreen and in silico iTope/TCED technologies to profile the immunogenicity of therapeutic antibodies as a part of Rotapharm Biotech Srl research and development programme in the field of musculoskeletal disorders.
"We are delighted to have been part of Rottapharma|Madaus's drug development programme" said Dr Matthew Baker. chief scientific officer and co-founder of Antitope adding, "our technologies have assisted Rottapharma|Madaus in pre-cinical assessment of lead compounds for potential immunogenicity."
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity.